Clinical trials: Dialysis Amyloidosis
Dialysis Amyloidosis
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Dialysis-related amyloidosis (DRA) is a serious complication of long-term hemodialysis (HD). Its pathogenic mechanism involves accumulation of β2-microglobulin (β2M) in the blood.
- Trial name
- NCT02952144
- Testing
- Lixelle® treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kaneka Medical America LLC